{"title":"General Genetic Testing and Care Services","description":"","products":[{"product_id":"egexosol","title":"Whole Exome Sequencing - Solo","description":"The Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding genes in the human genome (\u0026gt;18,000 genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years. \n\nIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974153728286,"sku":"EGEXOSOL","price":2950.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexoduo","title":"Whole Exome Sequencing - Duo","description":"The Whole Exome Sequencing- Duo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding genes in the human genome (\u0026gt;18,000 genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years. \n\nIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974153793822,"sku":"EGEXODUO","price":4050.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexotri","title":"Whole Exome Sequencing - Trio","description":"The Whole Exome Sequencing- Trio is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding genes in the human genome (\u0026gt;18,000 genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years. \n\nIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974153892126,"sku":"EGEXOTRI","price":5350.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"eggensol","title":"Whole Genome Sequencing - Solo","description":"The Whole Genome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our genome analysis evaluates all protein-coding genes in the human genome (\u0026gt;18,000 genes) as well as non-coding genes (\u0026gt;15,000 genes) and detects single nucleotide variants, small insertions and deletions, copy number variants, and large structural variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years. \n\nIn the course of carrying out a rigorous analysis of the genome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the genome testing. If we identify an incidental finding, we will report it in the primary genome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974153957662,"sku":"EGGENSOL","price":4650.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"eggenduo","title":"Whole Genome Sequencing - Duo","description":"The Whole Genome Sequencing- Duo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our genome analysis evaluates all protein-coding genes in the human genome (\u0026gt;18,000 genes) as well as non-coding genes (\u0026gt;15,000 genes) and detects single nucleotide variants, small insertions and deletions, copy number variants, and large structural variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\n\nIn the course of carrying out a rigorous analysis of the genome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the genome testing. If we identify an incidental finding, we will report it in the primary genome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974154023198,"sku":"EGGENDUO","price":6250.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"eggentri","title":"Whole Genome Sequencing - Trio","description":"The Whole Genome Sequencing- Trio is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our genome analysis evaluates all protein-coding genes in the human genome (\u0026gt;18,000 genes) as well as non-coding genes (\u0026gt;15,000 genes) and detects single nucleotide variants, small insertions and deletions, copy number variants, and large structural variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient’s case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\n\nIn the course of carrying out a rigorous analysis of the genome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the genome testing. If we identify an incidental finding, we will report it in the primary genome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings genes.\n\n\n","brand":"Medical Genetics Company","offers":[{"title":"Default Title","offer_id":44974154088734,"sku":"EGGENTRI","price":8950.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"myexomecare","title":"MyExomeCare","description":"\u003cp\u003eMyExomeCare provides a very cost-effective way to diagnose adult-onset genetic diseases such as those affecting the heart (high cholestrol and arrhythmia), the kidneys (kidney failure), and the brain (dementia and amyotrophic lateral sclerosis), just to name a few. MyExomeCare is designed to test close to 20,000 known Genes and 7,000 known genetic diseases all at once, thus representing a quick and effective way to establish the diagnosis in a timely manner.\u003c\/p\u003e","brand":"Medical Genetics Company","offers":[{"title":"Saudi National (0% VAT)","offer_id":60748665684254,"sku":"MyExomeCare-Saudi","price":2950.0,"currency_code":"SAR","in_stock":true},{"title":"Non-Saudi National (15% VAT included)","offer_id":60790652338462,"sku":"MyExomeCare-NonSaudi","price":3392.5,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/MyExomeCare-03-kit-concept.webp?v=1793563802"},{"product_id":"egcanmsi","title":"Microsatellite Instability by NGS - MSI","description":"\u003cp\u003eMicrosatellite instability testing is used to identify tumors caused by defective MMR by\u003cbr\u003ecomparing the number of nucleotide repeats in a panel of microsatellite markers in normal tissue with the\u003cbr\u003ethe number of tumor tissue from the same individual.\u003cbr\u003eMicrosatellite instability (MSI) is present if the number of repeats in the tumor and the normal tissue\u003cbr\u003ediffers.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440460574,"sku":"EGCANMSI","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egcantmb","title":"Tumor Mutational Burden by NGS - TMB","description":"\u003cp\u003eTumor Mutational Burden (TMB) gives us the total number of somatic mutations per megabase (Mb) of the coding region of a tumor genome. It serves as a biomarker for predicting response to immune checkpoint inhibitors, as tumors with high TMB may generate more neoantigens, enhancing immune recognition. TMB assessment in NGS involves analyzing single nucleotide variants (SNVs) and small insertions\/deletions (indels) while excluding germline mutations and known artifacts. Accurate TMB calculation requires high-depth sequencing, robust bioinformatics pipelines, and standardized cutoffs for clinical interpretation.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790440919326,"sku":"EGCANTMB","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egdnarel","title":"Relative DNA Profiling","description":"\u003cp\u003eRelative DNA Profiling is a comprehensive genetic relationship analysis that uses highly informative DNA markers to determine biological relationships between individuals. The test compares genetic profiles to evaluate the likelihood of relatedness and provides statistically supported conclusions regarding family relationships.\u003c\/p\u003e\u003cp\u003eThis service can be used to confirm or exclude a wide range of biological relationships, including parent-child, siblings, grandparents, avuncular (aunt\/uncle), cousins, and other extended family relationships. It is suitable for legal, immigration, inheritance, family reunification, and personal relationship verification, depending on the chain-of-custody requirements.\u003c\/p\u003e\u003cp\u003eThe test utilizes validated DNA profiling technology to deliver highly accurate, confidential, and reliable results, with comprehensive reporting and expert interpretation.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441312542,"sku":"EGDNAREL","price":1800.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egexocnv","title":"Clinical Exome Sequencing","description":"\u003cp\u003eClinical Exome Sequencing is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441345310,"sku":"EGEXOCNV","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexoduoc","title":"Whole Exome Sequencing - Duo with Copy Number Variation (CNV)","description":"\u003cp\u003eThe Whole Exome Sequencing- Duo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441378078,"sku":"EGEXODUOC","price":4500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexoduom","title":"Whole Exome Sequencing - Duo with Mitochondrial Genome Sequencing","description":"\u003cp\u003eThe Whole Exome Sequencing- Duo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441410846,"sku":"EGEXODUOM","price":4500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexofinf","title":"Female Infertility Panel","description":"\u003cp\u003eThe Female Infertility Panel is a comprehensive Next-Generation Sequencing (NGS) assay that analyzes genes associated with inherited causes of female infertility and reproductive dysfunction. The panel evaluates clinically relevant genetic variants linked to disorders such as primary ovarian insufficiency (POI), diminished ovarian reserve, oocyte maturation defects, ovarian dysgenesis, endocrine-related infertility, recurrent implantation failure, and other inherited reproductive conditions.\u003c\/p\u003e\u003cp\u003eBy identifying pathogenic variants, the panel supports the diagnosis of women with unexplained infertility, recurrent assisted reproductive technology (ART) failure, recurrent pregnancy loss with suspected genetic etiology, and a family history of reproductive disorders. Results assist clinicians in personalized fertility management, treatment planning, reproductive counseling, and informed family planning decisions.\u003c\/p\u003e\u003cp\u003eThe panel may include genes involved in:\u003c\/p\u003e\u003cp\u003eOvarian development and function\u003cbr\u003eFolliculogenesis and oocyte maturation\u003cbr\u003eHormonal signaling pathways\u003cbr\u003eGonadal differentiation\u003cbr\u003eMeiosis and DNA repair\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441443614,"sku":"EGEXOFINF","price":2550.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egexogi","title":"Comprehensive Gastrointestinal Disorders Panel","description":"\u003cp\u003eThe GI Comprehensive Panel is an NGS-based multigene assay that analyzes a broad spectrum of genes associated with inherited gastrointestinal disorders. The panel supports the diagnosis of patients with unexplained gastrointestinal symptoms, early-onset or familial gastrointestinal diseases, recurrent or chronic pancreatitis, hereditary colorectal cancer syndromes, gastrointestinal polyposis, inflammatory bowel diseases, and other inherited digestive disorders.\u003c\/p\u003e\u003cp\u003eThe panel includes genes associated with hereditary pancreatitis, such as PRSS1, SPINK1, CFTR, CTRC, CPA1, CASR, and other clinically relevant pancreatic disease genes, enabling comprehensive evaluation of patients with recurrent acute pancreatitis, chronic pancreatitis, or suspected inherited pancreatic disorders.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441541918,"sku":"EGEXOGI","price":2550.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egexomgs","title":"Whole Exome Sequencing with Mitochondrial Genome Sequencing","description":"\u003cp\u003eThe Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441574686,"sku":"EGEXOMGS","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexominf","title":"Men’s Infertility Genetic Panel","description":"\u003cp\u003eThis comprehensive panel analyzes key genetic factors that may contribute to male infertility, including mutations in genes involved in spermatogenesis and testicular function.\u003cbr\u003eThe panel is ideal for evaluating individuals with:\u003cbr\u003eAzoospermia (no sperm)\u003cbr\u003eSevere oligospermia (low sperm count)\u003cbr\u003eAbnormal sperm morphology or motility\u003cbr\u003eUnexplained infertility\u003cbr\u003eBy identifying genetic causes, this test can guide reproductive planning, eligibility for assisted reproductive technologies (ART), and inform the risk of transmission to offspring.\u003cbr\u003eKey components may include:\u003cbr\u003eCFTR gene mutations (linked to congenital absence of the vas deferens)\u003cbr\u003eOther fertility-related genes (e.g., NR5A1, TEX11, DMRT1)\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441607454,"sku":"EGEXOMINF","price":2550.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egexorap","title":"Whole Exome Sequencing - Rapid","description":"\u003cp\u003eThe Whole Exome Sequencing- Rapid is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the test cost and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings fall within Enigma Genomics' duty to notify policy, and there is no option to opt-out, even if the finding falls within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441771294,"sku":"EGEXORAP","price":3400.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexosolc","title":"Whole Exome Sequencing - Solo with Copy Number Variation (CNV)","description":"\u003cp\u003eThe Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790441902366,"sku":"EGEXOSOLC","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexosolm","title":"Whole Exome Sequencing - Solo with Mitochondrial Genome Sequencing","description":"\u003cp\u003eThe Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442066206,"sku":"EGEXOSOLM","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexosqm","title":"Whole Exome (Sequencing only) + Mitochondrial Genome","description":"\u003cp\u003eThe test analyzes the protein-coding regions of the genome (exome) and the entire mitochondrial genome, offering a comprehensive view of the genetic variations present.\u003cbr\u003eThe data will be delivered in its raw format, typically as FASTQ or VCF files, for further analysis by researchers, bioinformaticians, or laboratories. This option is suitable for users who wish to conduct their own detailed analysis or who do not require a clinical report.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442098974,"sku":"EGEXOSQM","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexossq","title":"Whole Exome Sequencing (Sequencing only)","description":"\u003cp\u003eWhole Exome Sequencing (Sequencing Only)\u003cbr\u003eWhole Exome Sequencing (WES) targets and sequences all protein-coding regions of the human genome — the exons — which represent approximately 1–2% of the genome but contain the majority of known disease-causing variants.\u003c\/p\u003e\u003cp\u003eThis test provides high-depth sequencing data for research or clinical analysis purposes. The “Sequencing Only” option includes raw sequencing data (FASTQ\/BAM\/VCF files) and quality metrics but does not include variant annotation, clinical interpretation, or report generation.\u003c\/p\u003e\u003cp\u003eApplications:\u003c\/p\u003e\u003cp\u003eIdentification of single nucleotide variants (SNVs) and small insertions\/deletions (indels) in coding regions\u003c\/p\u003e\u003cp\u003eResearch on genetic predisposition to diseases\u003cbr\u003eFurther downstream bioinformatics or clinical analysis\u003cbr\u003eDeliverables:\u003cbr\u003eRaw data files (FASTQ\/BAM\/VCF)\u003cbr\u003eSequencing quality report\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442131742,"sku":"EGEXOSSQ","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexotric","title":"Whole Exome Sequencing - Trio with Copy Number Variation (CNV)","description":"\u003cp\u003eThe Whole Exome Sequencing- Trio is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442164510,"sku":"EGEXOTRIC","price":5950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egexotrim","title":"Whole Exome Sequencing - Trio with Mitochondrial Genome Sequencing","description":"\u003cp\u003eThe Whole Exome Sequencing- Trio is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442197278,"sku":"EGEXOTRIM","price":5950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"eggenpren","title":"Prenatal Whole Genome Sequencing","description":"\u003cp\u003eIt provides comprehensive insight into both coding and non-coding regions of the genome, identifying potential single-nucleotide variants (SNVs), insertions\/deletions, structural variants, and copy number variations (CNVs).\u003cbr\u003eThis test is typically performed on samples obtained via amniocentesis or chorionic villus sampling (CVS), and is especially useful in cases where:\u003cbr\u003eRoutine prenatal screening or imaging (e.g., ultrasound) shows abnormalities\u003c\/p\u003e\u003cp\u003eThere’s a history of genetic disorders\u003cbr\u003ePrevious tests (karyotype, microarray) were inconclusive\u003cbr\u003eKey Benefits:\u003cbr\u003eHigh diagnostic yield for unexplained fetal anomalies\u003cbr\u003eDetection of rare genetic disorders\u003cbr\u003eInforms clinical decision-making during pregnancy\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442656030,"sku":"EGGENPREN","price":5000.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-carrier-v1.png?v=1793571522"},{"product_id":"eggensolb","title":"Whole Genome Sequencing - Solo - Bioinformatics Only","description":"\u003cp\u003eWhole Genome Sequencing - Solo - Bioinformatics Only\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790442688798,"sku":"EGGENSOLB","price":4650.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"eghisish","title":"In Situ Hybridization (ISH)","description":"\u003cp\u003eIn Situ Hybridization (ISH) is an advanced molecular diagnostic technique that identifies specific nucleic acid (DNA or RNA) targets within tissue sections or cytology specimens using labeled complementary probes. Unlike conventional molecular assays, ISH allows direct visualization of genetic alterations or infectious organisms within their histological context, enabling precise localization of molecular abnormalities in individual cells.\u003c\/p\u003e\u003cp\u003eISH plays a critical role in oncology, hematopathology, infectious disease diagnosis, and genetic testing. It is commonly used to detect gene amplifications, chromosomal rearrangements, deletions, copy number changes, viral genomes, and gene expression markers that assist in diagnosis, prognosis, therapeutic selection, and disease monitoring.\u003c\/p\u003e\u003cp\u003eDepending on the clinical application, ISH may be performed using Fluorescence In Situ Hybridization (FISH) or Chromogenic In Situ Hybridization (CISH) technologies.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790443868446,"sku":"EGHISISH","price":1300.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"eghlacii","title":"Celiac Disease HLA-DQ2\/DQ8 Genotyping","description":"\u003cp\u003eCeliac Disease HLA-DQ2\/DQ8 Genotyping is an NGS-based molecular genetic test performed at Enigma Genomics to assess an individual’s genetic predisposition to celiac disease by analyzing relevant variants within the HLA-DQA1 and HLA-DQB1 genes associated with the HLA-DQ2 and HLA-DQ8 haplotypes.\u003c\/p\u003e\u003cp\u003eThe test identifies the presence or absence of celiac disease-associated HLA-DQ2 and HLA-DQ8 genetic profiles. The presence of these haplotypes indicates genetic susceptibility to celiac disease but does not confirm the diagnosis, as these variants are also present in a proportion of the general population. Conversely, the absence of the relevant HLA-DQ2\/DQ8 risk profiles makes celiac disease highly unlikely.\u003c\/p\u003e\u003cp\u003eResults Will be interpreted in conjunction with the patient’s clinical presentation, serological testing, family history, and other relevant clinical findings.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790443933982,"sku":"EGHLACII","price":1800.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"eghlafull","title":"HLA Complete Typing: Class I \u0026 II","description":"\u003cp\u003eOverview\u003cbr\u003eHLA Typing High Resolution is a molecular genetic test that identifies the HLA alleles of an individual at six clinically important loci: HLA-A, HLA-B, HLA-C (Class I) and HLA-DRB1, HLA-DQB1, HLA-DPB1 (Class II). The HLA genes are located on chromosome 6p21 (MHC region) and are among the most polymorphic genes in the human genome. They play a central role in immune recognition and in distinguishing self from non-self.\u003c\/p\u003e\u003cp\u003eMethodology\u003cbr\u003eThe test uses DNA extracted from the patient’s sample, followed by targeted amplification of the HLA loci and next-generation sequencing (NGS). Results are analyzed with specialized HLA bioinformatics software and compared against the IPD-IMGT\/HLA database, which gives allele-level (high-resolution) typing and reduces the ambiguities that low- and intermediate-resolution methods leave.\u003cbr\u003eGenes Covered\u003c\/p\u003e\u003cp\u003eClass\tGenes\u003cbr\u003eClass I\tHLA-A, HLA-B, HLA-C\u003cbr\u003eClass II\tHLA-DRB1, HLA-DQB1, HLA-DPB1\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790443966750,"sku":"EGHLAFULL","price":2800.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmetab","title":"ENIGMA EasyCheck","description":"\u003cp\u003eThe EasyCheck is a comprehensive, at-home wellness test that analyzes your blood using advanced metabolomics to measure hundreds of key biomarkers linked to your metabolic health. By examining the molecular signals in your body, the test provides a detailed assessment of your risk for several chronic conditions, including cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.\u003cbr\u003eThe results offer a science-backed snapshot of your internal health and highlight early imbalances—empowering you with actionable insights to prevent disease and optimize long-term well-being, all from the comfort of your home.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444327198,"sku":"EGMETAB","price":1200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmgs","title":"Mitochondrial Genome Analysis","description":"\u003cp\u003eAnalysis of mitochondrial DNA variants is crucial for understanding the genetic basis of mitochondrial diseases,\u003cbr\u003ewhich are caused by mutations in mitochondrial genes that often affect tissues and organs with high energy\u003cbr\u003edemands, such as muscles and the nervous system. These diseases can manifest as a wide range of symptoms,\u003cbr\u003eincluding muscle weakness, neurological problems, and developmental delays. Identifying pathogenic mutations\u003cbr\u003ehelps in diagnosing mitochondrial disorders and developing targeted therapies.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444491038,"sku":"EGMGS","price":2300.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmicbim","title":"ENIGMA Microbiome","description":"\u003cp\u003eThe Microbiome Genetic Analysis using Whole Metagenome Sequencing (WMS) is a comprehensive test that examines the total genetic content of microbial communities present in a stool sample. Unlike 16S rRNA testing, WMS allows species- and strain-level resolution and enables the identification of bacteria, viruses, fungi, and archaea.\u003cbr\u003eThis analysis provides critical insights not only into microbial diversity but also into the functional genes present, such as those involved in metabolism, immune modulation, antibiotic resistance, and vitamin synthesis.\u003cbr\u003eTest Highlights:\u003cbr\u003eTechnology: Whole Metagenome Sequencing (WMS)\u003cbr\u003eSample Type: Stool\u003cbr\u003eCoverage: Full DNA sequencing of all microbial genomes\u003cbr\u003eResolution: Species \u0026amp; strain level\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444523806,"sku":"EGMICBIM","price":1850.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmispcr","title":"Polymerase chain reaction","description":"\u003cp\u003ePCR is a versatile technique used in medical diagnostics, genetics, forensics, environmental monitoring, and more. It amplifies and detects DNA sequences accurately, enabling applications such as pathogen detection, genetic research, and forensic analysis.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444556574,"sku":"EGMISPCR","price":1750.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmlpa","title":"MLPA Test – Gene Deletion\/Duplication","description":"\u003cp\u003e- MLPA uses pairs of oligonucleotide probes – small molecules of DNA that are designed to hybridise with a specific genomic sequence. Multiple pairs of probes can be multiplexed in the same reaction, for example to screen for all exons of a gene.- The probes bind only where their exact target sequence is present. If the probes in a pair bind immediately next to each other, their ends ligate (join together).- There is one primer binding site on the end of each of the probes in the pair. PCR amplification therefore only occurs if probes in a pair have ligated.- Amplification products are separated by length using capillary electrophoresis.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444589342,"sku":"EGMLPA","price":1200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egmlpapren","title":"MLPA Test – Gene Deletion\/Duplication with MCC","description":"\u003cp\u003eMLPA (Multiplex Ligation-dependent Probe Amplification) is a molecular genetic technique designed to identify copy number variations (CNVs), specifically deletions and duplications in targeted genes or chromosomal regions. Unlike sequencing, which detects single nucleotide variants (SNVs) or small indels, MLPA is highly sensitive for detecting larger structural changes within genes that may cause disease.\u003cbr\u003eFor prenatal testing, Maternal Cell Contamination (MCC) analysis is performed in parallel using a maternal blood sample. This step ensures that the DNA analyzed from the amniotic fluid is purely fetal and free from maternal DNA contamination, providing reliable and accurate diagnostic results.\u003cbr\u003eTypical clinical applications include confirming suspected genetic syndromes, carrier testing, or prenatal diagnosis of known familial variants.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444622110,"sku":"EGMLPAPREN","price":2300.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egnutri","title":"ENIGMA Nutrition Program","description":"\u003cp\u003eOur Genetic Nutrition \u0026amp; Weight Management Program provides personalized insights into how your genetics affect metabolism, dietary preferences, and nutrient absorption. With this information, we offer tailored dietary recommendations designed to optimize your health and prevent potential nutrition-related issues.\u003c\/p\u003e\u003cp\u003eBy integrating genetics into your nutrition plan, you'll gain a deeper understanding of what your body truly needs for long-term wellness. Unlock the power of personalized nutrition. Our package uses genetics to uncover your unique dietary needs and deliver science-based dietary suggestions for optimal well-being. Improve your health for the long haul with a nutritional plan tailored to you.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444753182,"sku":"EGNUTRI","price":1200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egpcrfx","title":"Fragile X Test (FXS)","description":"\u003cp\u003eThe Fragile X Syndrome test is a molecular genetic test that analyses the FMR1 gene on the X chromosome to determine the number of CGG trinucleotide repeats. An abnormal expansion of these repeats leads to silencing of the FMR1 gene, which prevents the production of the FMRP protein, essential for normal brain development.\u003cbr\u003eThis test is used to diagnose:\u003cbr\u003eFragile X Syndrome (FXS) in individuals showing developmental delays, learning disabilities, or autism-like behavior.\u003cbr\u003eCarrier status in individuals with a family history of FXS.\u003cbr\u003eRelated conditions like Fragile X-associated Tremor\/Ataxia Syndrome (FXTAS) and Fragile X-associated Primary Ovarian Insufficiency (FXPOI) in premutation carriers.\u003cbr\u003eTesting is performed using:\u003cbr\u003ePCR to estimate CGG repeat size.\u003cbr\u003eEarly diagnosis allows for timely interventions, appropriate therapies, and genetic counselling for affected individuals and their families.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444949790,"sku":"EGPCRFX","price":1700.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egpcrfxpen","title":"Prenatal Fragile X testing","description":"\u003cp\u003eThe most common inherited cause of mental retardation affecting\u003cbr\u003eapproximately 1 in 4000–6000 male and 1 in 8000–10,000 female. \u003cbr\u003eThe syndrome is associated with an abnormality of the\u003cbr\u003eFragile X Mental Retardation 1 (FMR1) gene located in a fragile site at Xq27.3. This alteration originates from an unstable expansion of CGG trinucleotide repeats within the 5′untranslated region of the FMR1 gene.  \u003cbr\u003eThe normal Individuals have\u003cbr\u003eapproximately 5 to 40 CGG repeatsand individuals who are carriers for FXS have 55 to 200 CGG repeatswhich is classified\u003cbr\u003eas premutation, it is associated with pathological conditions that premature ovarian failurein females and fragile X- associated tremor\/ataxia syndrome (FXTAS) in males. \u003cbr\u003eAlso, the FXS is characterized by the CGG full mutation and\u003cbr\u003emethylation of the cytosine bases, which leads to silencing of transcription and abnormal or absence of the encoded Fragile\u003cbr\u003eX mental retardation protein (FMRP). FMRP is a major protein regulator of the translation of many mRNAs involved in\u003cbr\u003esynaptic plasticity. Since the mutation is X-linked, males are more severely affected than females and males with FXS\u003cbr\u003epredominantly exhibit mental retardation, autism, and behavioral alteration.FXS inheritance depends on the number of\u003cbr\u003eCGG repeats within the promoter of the FMR1 gene and transition from the premutation to full mutationallele can occur\u003cbr\u003ebecause of the expansion phenomenon during the transmission of the maternal X chromosome and rarely the paternal X\u003cbr\u003echromosome carrying a premutation allele to offspring (1-3).\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790444982558,"sku":"EGPCRFXPEN","price":2400.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-carrier-v1.png?v=1793571522"},{"product_id":"egpncspm","title":"Prenatal Comprehensive Carrier Screen Panel with MCC","description":"\u003cp\u003e- This test enables the identification of the carrier status of 556 genetic disorders.\u003cbr\u003e- This test is tailored to detect individuals harboring genetic mutations associated with specific disorders, even if they exhibit no symptoms.\u003cbr\u003e- This test is recommended for individuals of reproductive age or families with a genetic predisposition, either before or during pregnancy.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445277470,"sku":"EGPNCSPM","price":1200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-couple-v1.png?v=1793571568"},{"product_id":"egprs","title":"Enigma RiskMap","description":"\u003cp\u003eEnigma RiskMap\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445375774,"sku":"EGPRS","price":1650.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egprsgen","title":"Polygenic Chronic Disease Risk","description":"\u003cp\u003ePolygenic chronic disease risk refers to the predisposition or likelihood of developing certain chronic conditions, such as heart disease, diabetes, or certain types of cancer, based on the combined influence of multiple genes. Unlike diseases caused by a single gene mutation, polygenic diseases result from the complex interplay of numerous genetic variants across an individual's genome. These variants, each contributing a small effect, collectively impact an individual's susceptibility to chronic conditions, often influenced by environmental factors, lifestyle, and personal health choices. Understanding one's polygenic risk can offer insights into the likelihood of developing these diseases, aiding in proactive health management, personalized preventive measures, and tailored treatment strategies.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445408542,"sku":"EGPRSGEN","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egprsplus","title":"Polygenic Chronic Disease Risk Extended","description":"\u003cp\u003ePolygenic Chronic Disease Risk Extended\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445441310,"sku":"EGPRSPLUS","price":1500.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egresdis","title":"Respiratory Disorders Genetic Panel","description":"\u003cp\u003eLong Description:\u003c\/p\u003e\u003cp\u003eThe Respiratory Disorders Genetic Panel is a comprehensive next-generation sequencing (NGS) assay designed to detect genetic variants associated with a wide range of inherited respiratory conditions. The panel covers clinically relevant genes linked to disorders such as cystic fibrosis, primary ciliary dyskinesia, alpha-1 antitrypsin deficiency, interstitial lung disease, pulmonary fibrosis, pulmonary arterial hypertension, bronchiectasis, and other genetic respiratory conditions.\u003c\/p\u003e\u003cp\u003eThis test enables high-resolution genetic analysis to support early diagnosis, differential diagnosis, and risk assessment. It helps clinicians guide patient management, family screening, and personalized treatment strategies.\u003c\/p\u003e\u003cp\u003eThe assay is performed using high-quality NGS technology with robust bioinformatics analysis to ensure accurate variant detection and interpretation based on current clinical guidelines.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445736222,"sku":"EGRESDIS","price":2550.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egresexo","title":"Whole Exome Sequencing - Research","description":"\u003cp\u003eThe Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years. In the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding falls within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790445768990,"sku":"EGRESEXO","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"egtruage","title":"Enigma TruAge","description":"\u003cp\u003eEnigma TruAge\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790449602846,"sku":"EGTRUAGE","price":1000.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"egwellness","title":"EGWELLNESS","description":"\u003cp\u003eGain insights into nutrition, fitness, skin and hair health, mental health, sleep patterns —all tailored to your unique genetic makeup. This all-in-one solution empowers you to understand your body better and optimize your overall well-being, guiding you toward a healthier, more balanced life.\r\u003c\/p\u003e\u003cp\u003e\r\u003c\/p\u003e\u003cp\u003eTransform your health and well-being with our Comprehensive Wellness Package. Discover personalized insights and solutions for nutrition, fitness, skin and hair health, mental health, and sleep patterns, all based on your specific genetic makeup. Our holistic approach combines all our specialized packages into one comprehensive solution, giving you the tools to better understand and optimize your overall wellness.\u003c\/p\u003e","brand":"Medical Genetics Company","offers":[{"title":"Saudi National (0% VAT)","offer_id":60790449733918,"sku":"EGWELLNESS-Saudi","price":3500.0,"currency_code":"SAR","in_stock":true},{"title":"Non-Saudi National (15% VAT included)","offer_id":60790655713566,"sku":"EGWELLNESS-NonSaudi","price":4025.0,"currency_code":"SAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/MyWellnessCare-03-kit-concept.webp?v=1793563841"},{"product_id":"ytexosol","title":"Whole Exome Sequencing - Solo","description":"\u003cp\u003eThe Whole Exome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our exome analysis evaluates almost all protein-coding Genes in the human genome (\u0026gt;18,000 Genes in a single assay) and detects single nucleotide variants, small insertions and deletions, and intragenic copy number variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the exome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the exome testing. If we identify an incidental finding, we will report it in the primary exome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790449832222,"sku":"YTEXOSOL","price":2950.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-exome-v1.png?v=1793571352"},{"product_id":"ytgensol","title":"Whole Genome Sequencing - Solo","description":"\u003cp\u003eThe Whole Genome Sequencing- Solo is intended to identify gene\/variant combinations that may aid in the diagnosis of patients with rare genetic disorders. Our genome analysis evaluates all protein-coding Genes in the human genome (\u0026gt;18,000 Genes) as well as non-coding Genes (\u0026gt;15,000 Genes) and detects single nucleotide variants, small insertions and deletions, copy number variants, and large structural variants. Artificial intelligence (AI)-powered software weighs clinical and genetic information to identify the variants most relevant to each patient's case. Routine case-level reanalysis is included in the cost of the test and performed every 6-12 months for a minimum of 2 years.\u003c\/p\u003e\u003cp\u003eIn the course of carrying out a rigorous analysis of the genome sequence, this test may occasionally incidentally discover genetic changes that are of medical importance but are not directly relevant to the primary reason for the genome testing. If we identify an incidental finding, we will report it in the primary genome report with an appropriate explanation. Enigma Genomics will not report any incidental findings associated with adult-onset neurodegenerative disorders for which there are no interventions available. In keeping with medical practice best standards, incidental findings are considered to fall within Enigma Genomics' duty to notify policy, and there is no option to opt out, even if the finding happens to fall within one of the ACMG secondary findings Genes.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790449963294,"sku":"YTGENSOL","price":4650.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"ytmetab","title":"EasyCheck","description":"\u003cp\u003eThe EasyCheck is a comprehensive, at-home wellness test that analyzes your blood using advanced metabolomics to measure hundreds of key biomarkers linked to your metabolic health. By examining the molecular signals in your body, the test provides a detailed assessment of your risk for several chronic conditions, including cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.\u003cbr\u003eThe results offer a science-backed snapshot of your internal health and highlight early imbalances—empowering you with actionable insights to prevent disease and optimize long-term well-being, all from the comfort of your home.\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790449996062,"sku":"YTMETAB","price":1200.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"},{"product_id":"ytmicbim","title":"Microbiome","description":"\u003cp\u003eThe Microbiome Genetic Analysis using Whole Metagenome Sequencing (WMS) is a comprehensive test that examines the total genetic content of microbial communities present in a stool sample. Unlike 16S rRNA testing, WMS allows species- and strain-level resolution and enables the identification of bacteria, viruses, fungi, and archaea.\u003cbr\u003eThis analysis provides critical insights not only into microbial diversity but also into the functional genes present, such as those involved in metabolism, immune modulation, antibiotic resistance, and vitamin synthesis.\u003cbr\u003eTest Highlights:\u003cbr\u003eTechnology: Whole Metagenome Sequencing (WMS)\u003cbr\u003eSample Type: Stool\u003cbr\u003eCoverage: Full DNA sequencing of all microbial genomes\u003cbr\u003eResolution: Species \u0026amp; strain level\u003c\/p\u003e","brand":"Enigma Genomics","offers":[{"title":"Default Title","offer_id":60790450028830,"sku":"YTMICBIM","price":1850.0,"currency_code":"SAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/files\/enigma-test-icon-general-genome-v1.png?v=1793571358"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/6678\/6590\/collections\/icon-general.png?v=1685834412","url":"https:\/\/shop.enigmagenomics.com\/en\/collections\/general.oembed?page=6","provider":"Enigma Genomics","version":"1.0","type":"link"}